Duration of Platelet Inhibition by Aspirin

Completed

• Conditions: Coronary Artery Disease
• Interventions: Other: Platelet aggregation

• Registration Number: NCT00671021
• Lead Sponsor: Hopital du Sacre-Coeur de Montreal

Brief Summary

The well established importance of regular aspirin administration stands on firm grounds, as large meta-analyses have shown this therapy to significantly reduce the risk of death. However, not all patients benefit of aspirin administration to the same extent, thus high-lighting a sub-population of patients with inadequate platelet response to ASA. The mechanisms underlying reduced ASA efficacy remain elusive. A recent report has suggested that platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase enzyme, once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients.

The current study aims to evaluate, in patients suffering from stable coronary artery disease, the stability of platelet inhibition by aspirin during the normal once daily dosing regimen.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-04-30
• Study First Submitted QC: 2008-05-01
• Study First Posted: 2008-05-02
• Study Start: 2008-07
• Primary Completion: 2009-01
• Study Completion: 2009-01
• Status Verified: 2009-03
• Last Update Submitted: 2012-08-20
• Last Update Posted: 2012-08-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Patients suffering from stable CAD, on chronic ASA therapy
• Patients willing to participate in the study and to sign the informed consent form

Read More

Exclusion Criteria

• Acute coronary syndrome or revascularization in the last 3 months prior to enrolment
• Concurrent ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), clopidogrel, ticlopidine, dipyridamole, warfarin or acenocoumarol
• Frequent use (more than once a week) of non-prescription NSAIDs or drugs containing ASA in the 10 days preceding enrolment
• Major surgical procedure within 1 month before enrolment
• Hemorrhagic diathesis or known platelet dysfunction
• Platelet count outside the 100 to 450 x109/L range for technical reasons
• Hematocrit < 25% or haemoglobin < 100 g/L
• Patient undergoing dialysis for chronic renal failure
• Patient found to be ASA resistant

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Platelet aggregation	Patients suffering from stable CAD, on chronic ASA therapy

Primary Outcome Measures

Name	Time	Method
Platelet aggregation TxA2 formation

Trial Locations

Locations (1)

Hôpital du Sacré-Coeur de Montréal; 🇨🇦 Montreal, Quebec, Canada